Genmab — November 2013
-
"
This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)." -
Var faktisk ikke klar over at vi fik sådanne data
-
Gazyva comes with a boxed warning about the possibility that the Hepatitis B virus could reactivate and it could cause PML (progressive multifocal leukoencephalopathy). PML is a rare brain disorder that damages the material which protects the nerves in the brain.
-
lyder hyggeligt
-
BendOfa refractory CLL: The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% CI, 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months.
-
accepted article preview 13 November 2013; doi: 10.1038/leu.2013.334 http://www.nature.com/leu/journal/vaop/naam/abs/leu2013334a.html
-
Ja - arzerra er ikke helt uden virkning
-
det eneste problem med de resultater er efterhånden, at CR er lidt for høj....
-
vi fik vist ikke markeret denne - http://seekingalpha.com/currents/post/1410482 det er btd kandidat nr 2, der bliver godkendt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind